कंपनी का अवलोकन
OSR Holdings, Inc. operates as a healthcare holding company dedicated to developing a portfolio of therapies and healthcare solutions across the United States, Switzerland, and South Korea. The firm focuses specifically on creating immunotherapy products, such as VXM01, which serves as an immuno-oncology candidate targeting glioblastoma and is currently undergoing phase 2 clinical trials. This biotechnology entity functions within the broader Healthcare sector and the specialized Biotechnology industry, where it aims to advance medical treatments through research and development rather than manufacturing or selling established consumer goods. The company's current market capitalization stands at $16.30M, while its annual revenue for the trailing twelve months (TTM) is recorded at $2.91M; employee count is listed as N/A in available data. These valuation and revenue metrics indicate that OSR Holdings, Inc. operates on a small-cap scale, suggesting it is an early-stage or niche player within the immunotherapy landscape rather than a large-cap established pharmaceutical firm. The low market capitalization relative to the biotechnology sector generally implies higher risk and potential for significant volatility, as the company's financial stability relies heavily on the successful progression of its clinical pipeline and limited existing revenue streams.
वित्तीय स्वास्थ्य
OSR Holdings, Inc. reported a revenue of $2.91M for the trailing twelve months, yet it simultaneously recorded a net income of $-18,010,900 and an EBITDA of $-9,029,896. The substantial disparity between the positive revenue of $2.91M and the significantly negative net income reveals a cost structure characterized by heavy operating expenses, likely driven by clinical trial costs and research expenditures common in biotechnology. Despite the net income loss, the company generated a free cash flow of $9.38M, which indicates a degree of financial flexibility by allowing the firm to fund operations without immediate reliance on external equity financing. However, the gross margin stands at 19.1%, while the operating margin is an alarming -1674.8% and the profit margin is 0.0%, highlighting severe inefficiencies or one-time losses impacting the bottom line. On the liability side, the company holds $1.70M in cash against $4.40M in debt, resulting in a debt-to-equity ratio of 3.47, which suggests a highly leveraged balance sheet rather than a conservative one. This leverage is further exacerbated by a current ratio of 0.16, indicating that the company's current assets are insufficient to cover its current liabilities, pointing to potential short-term liquidity challenges. Furthermore, the return on equity (ROE) is -20.0% and the return on assets (ROA) is -6.6%, metrics that reveal management has been unable to generate positive returns on shareholder capital or the asset base during the reporting period.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio and forward P/E ratio are both listed as N/A due to the company's lack of earnings, which implies that traditional valuation based on earnings multiples is not applicable at this time. The price-to-book ratio is recorded at 0.14, indicating that the market values the company at a fraction of its book value, suggesting a deep discount or a lack of market confidence in the tangible assets backing the stock. Alternative valuation metrics show a price-to-sales ratio of 5.61 and an EV/EBITDA of -7.58, which suggests the market is pricing the company based on its revenue potential and asset backing rather than profitability, given the negative earnings multiple. The stock has traded within a 52-week range with a high of $1.79 and a low of $0.38, meaning the current price sits somewhere within this volatile band, reflecting the uncertainty surrounding the phase 2 clinical trial of VXM01. The beta value is 0.59, which indicates that the stock price volatility is lower than the broader market average, suggesting that despite the financial risks, the asset itself does not amplify market movements as aggressively as high-beta biotechnology stocks. This lower beta might provide some relative stability, though the negative EV/EBITDA and high debt levels continue to pose significant risks to the share price.
Growth & Income
The revenue growth year-over-year is -58.3%, while earnings growth is N/A due to the company's current losses, implying that the firm is not growing its top line and is instead contracting in terms of revenue generation. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute earnings to shareholders, as there are no earnings to distribute in the first place. Instead of paying dividends, the company retains its limited cash reserves and free cash flow to reinvest into its R&D efforts and sustain its clinical trials for VXM01. The overall growth and income profile of OSR Holdings, Inc. is currently defined by revenue contraction and a complete absence of income generation, positioning the company as a pure-play speculative asset dependent entirely on future clinical success rather than current operational profitability or dividend income.